Donor-derived cell-free DNA

Summary

The abstract of the review by Burman and colleagues names this candidate biomarker (graft-derived DNA circulating in the blood). The abstract states that the biomarkers named may aid risk stratification, patient enrichment and endotype-guided trials. No performance data are stated, and this record is a stub that is unverified beyond the abstract. Only the abstract of the source review was read; the full text was not read.

Sources and links

• Burman et al. 2026, J Heart Lung Transplant (DOI; abstract only was read) (primary)
• PubMed record (PMID 42854767)

Related

Links from this record

• named in (abstract only): CLAD: translating basic science to clinical practice
• candidate for endotype-guided use: Molecular endotypes of CLAD (proposed framework)

Linked from (derived)

• Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
• reports: Donor-derived cell-free DNA predicts allograft failure and mortality after lung transplantation
• evidence for: Donor-derived cell-free DNA in chronic lung allograft dysfunction phenotypes: a pilot study
• supports: Higher Molecular Injury at Diagnosis of Acute Cellular Rejection Increases the Risk of Lung Allograft Failure: A Clinical Trial
• discusses: Novel biomarkers of chronic lung allograft dysfunction: is there anything reliable?
• affects: Biomarker findings are hard to validate and generalise across centres
• affects: CLAD is recognised late and no biomarker is validated for early warning

Known gaps in this record

• full text of the source review not read, so the evidence, citations and level of agreement for this item are missing
• funding and conflicts of interest of the source review not read
• assay, performance and validation status not recorded